BridgeBio Oncology Therapeutics, Inc.
BBOT · XNASCIK 1869105fmd_0VPJH1KHHHYCJYY90BWS6Q5QPGManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2023 to Sep 30, 2026, 12 periods
| Line item | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Investment banking revenue | – | 0 | – |
| Research and development | – | 73 | 121 |
| Total operating expenses | – | 81 | 146 |
| Operating income | (0) | (81) | (146) |
| Interest and investment income | – | 8 | – |
| Other non-operating income (expense) | – | 7 | 12 |
| Income tax expense | – | 0 | 0 |
| Net income | (0) | (74) | (134) |